fda compounding semaglutide warning letters september 2025 Out of Shortage, Into Controversy: The Fight Over GLP-1 FDA unleashes warning letters to

GLP-1 Receptors in the Skin Though GLP-1Rs have been found to be expressed in skin, their role is still not fully understood (Figure 1)

Consent for Publication All authors have read, approved the manuscript and provided their consent for publication

The rise of weight loss drug copycats The KFF Health Tracking Poll from May 2024 provides significant insights into the publics use and perceptions of GLP-1 drugs

Multiple dosage options available

Retatrutide (LY3437943), developed by Eli Lilly, is an investigational once-weekly injectable triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously

Shimizu, T